Life Sciences

Nuclea Biotechnologies Inc., which has operations in Worcester, announced that federal regulators have classified its cell metabolism measurement device as having low to moderate risk.

Marlborough-based Boston Scientific Corp. has received federal approval for its latest stent system designed to treat coronary artery disease.

Karyopharm Therapeutics, a life sciences startup, was a rising star in Natick until the company announced last month it was moving to a bigger headquarters in Newton at the end of July. One reason? There wasn't enough laboratory space to expand.

Home to 11 percent of American drug development and more than a fifth of all U.S. biotech venture capital, Massachusetts has particularly piqued the interests of Israelis with life sciences backgrounds.

In what has been termed the biggest corporate takeover of 2014 to date, Illinois-drug maker AbbVie, which employs about 700 in Worcester at a research and development facility, has agreed to buy Dublin-based Shire in a $54 billion deal announced Friday morning.

A $420,000 grant from the National Institutes of Health (NIH) will allow a team of Worcester Polytechnic Institute researchers to test a plant-based therapy WPI is developing for the treatment of malaria.

Boston Scientific has launched European sales of products designed to treat peripheral artery and aortic valve diseases.

VitaThreads, a life sciences firm founded in 2012 by two Worcester Polytechnic Institute (WPI) professors, said its signature product has passed a milestone after its testing in animals.

Just weeks after winning federal approval for its home electronic exoskeleton, ReWalk Robotics of Marlborough has filed for an initial public offering of stock with the U.S. Securities and Exchange Commission (SEC).

Central Massachusetts is seen as an emerging leader in manufacturing, life sciences and health care in a recent report released by Citizens Bank.